Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERC1671 Combination Therapy for Recurrent Glioblastoma
NCT05366062Phase 2Not yet recruiting
- Sponsor
- Epitopoietic Research Corporation
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Sitoiganap in glioblastoma (GBM), sponsored by Epitopoietic Research Corporation. Primary endpoint: Overall Survival at 12 months. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
Sitoiganap
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05366062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366062.